

COVID-19 in solid organ transplant hospitalized patients, a matched control study

STUDY POPULATION

Follow-up time



28 days or
until censored

Controls


166

66.0 years, 73.5% male


Solid organ
transplant
(SOT)
patients

46

62.7 years, 71.7% male



30



13



3


AIM: to compare clinical outcomes of COVID-19 in SOT recipients with non-transplant COVID-19 patients.

MAIN OUTCOME:



Tendency toward
higher mortality
in SOT patients:

- Controls: **22.9%**
- SOT patients: **37%**



27%



54%



67%

SECONDARY OUTCOMES:

- **22.2%** of SOT patients required **admission to intensive care unit (ICU)**



- **SOT patients' immunosuppression was modified during hospitalization:**

91.3% were affected by potential/confirmed drug-drug interactions

71.7% discontinued immunosuppressants

Miarons et al. *Transplantation*. 2021

@TransplantJrnl

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved

Transplantation[®]

